Search
Edecesertib
go.drugbank.com/drugs/DB18917InvestigationalEdecesertib is under investigation in clinical trial NCT05629208 (Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)).
Synonyms: 3-Pyridinecarboxamide, 4-[[(1R)-1-cyanoethyl]amino]-6-(3-cyanopyrrolo[1,2-b]pyridazin-7-yl)-N-[(2R)-2-fluoro-3-hydroxy-3-methylbutyl]-, 4-{[(1R)-1-cyanoethyl]amino}-6-(3-cyanopyrrolo[1,2- b]pyridazin-7-yl)-N-[(2R)-2-fluoro-3-hydroxy-3- methylbutyl]pyridine-3-carboxamideNelmastobart
go.drugbank.com/drugs/DB19000InvestigationalNelmastobart is under investigation in clinical trial NCT05990543 (Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer).
Gamma cyclodextrin
go.drugbank.com/drugs/DB19173InvestigationalGamma cyclodextrin is under investigation in clinical trial NCT03931057 (The use of ADV6209 for Premedication in Pediatric Anesthesia).
Synonyms: -d-glucopyranosyl)Solrikitug
go.drugbank.com/drugs/DB19301InvestigationalSolrikitug is under investigation in clinical trial NCT06496607 (A Study to Evaluate Solriktug in Adult Participants With Asthma).
Cediranib
go.drugbank.com/drugs/DB04849InvestigationalThe novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro.
Candoxatril
go.drugbank.com/drugs/DB00616ExperimentalCandoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.
Sulfametopyrazine
go.drugbank.com/drugs/DB00664ApprovedWithdrawnLong-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.
Cobolimab
go.drugbank.com/drugs/DB16372InvestigationalCobolimab is under investigation in clinical trial NCT04655976 (Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants).
Rulonilimab
go.drugbank.com/drugs/DB18922InvestigationalRulonilimab is under investigation in clinical trial NCT05408221 (The Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma).